| Trevena Inc (TRVN) | |||
|---|---|---|---|
| 0.39 -0.001 (-0.26%) | 04-29 09:30 | ||
| Open: | 0.39 | Pre. Close: | 0.391 |
| High: | 0.39 | Low: | 0.39 |
| Volume: | 542 | Market Cap: | 6(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 0.50 One year: 0.59 |
| Support: | Support1: 0.30 Support2: 0.25 |
| Resistance: | Resistance1: 0.43 Resistance2: 0.51 |
| Pivot: | 0.39 |
| Moving Averages: | MA(5): 0.39  MA(20): 0.39 MA(100): 0.57 MA(250): 0.74 |
| MACD: | MACD(12,26): -0.03 Signal(12,26,9): -0.03 |
| %K %D: | %K(14,3): 65.98 %D(3): 62.43 |
| RSI: | RSI(14): 42.87 |
| 52-Week: | High: 3.28 Low: 0.3 Change(%): -39.7 |
| Average Vol(K): | 3-Month: 214 10-Days: 600 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 0.411 - 0.413 | 0.413 - 0.414 |
| Low: | 0.375 - 0.378 | 0.378 - 0.379 |
| Close: | 0.387 - 0.39 | 0.39 - 0.393 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TRVN ] has closed below upper band by 49.0%. Bollinger Bands are 38.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. |
| Stock chart |
|---|
 |
| Stock News |
|---|
|
Mon, 01 Apr 2024 Trevena: Q4 Earnings Snapshot - Quartz Mon, 01 Apr 2024 Trevena Inc Unveils Updated Corporate Strategy Presentation - TipRanks.com - TipRanks Wed, 06 Mar 2024 Trevena faces Nasdaq delisting over share price By Investing.com - Investing.com Thu, 01 Feb 2024 Trevena Inc Elevates Barry Shin to Executive VP and CFO - TipRanks.com - TipRanks Wed, 15 Nov 2023 Trevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Call Transcript - Yahoo Finance Mon, 08 May 2023 Why Is Trevena (TRVN) Stock Up 165% Today? - InvestorPlace |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Capital Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | -21.94 |
| Shares Float (M) | |
| % Held by Insiders | 18320000.00 |
| % Held by Institutions | 18100000.00 |
| Shares Short (K) | |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | |
| Book Value (p.s.) | -3.160 |
| Profit Margin | |
| Operating Margin | 12.00 |
| Return on Assets (ttm) | 374.4 |
| Return on Equity (ttm) | -49.4 |
| Qtrly Rev. Growth | 14.6 |
| Gross Profit (p.s.) | |
| Sales Per Share | -216.196 |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | -34950000.00 |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | -0.12 |
| Price to Sales | |
| Price to Cash Flow | |
| Stock Dividends | |
|---|---|
| Dividend | 112780.000 |
| Dividend Yield | 288439.91 |
| Dividend Growth | 81760.000 |
